Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8 | $6 | $6 | $6 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $8 | $7 | $7 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 36.3% | 421.2% | 557.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.8% | 83.4% | 76.3% | 54.7% |
| EBITDA | -$0 | -$0 | -$1 | -$0 |
| % Margin | -79.8% | -154.2% | -1,034.1% | -4,688.1% |
| Net Income | -$0 | -$0 | -$1 | -$0 |
| % Margin | -104% | -180.5% | -1,139.6% | -4,931.6% |
| EPS Diluted | -6.53 | -8.55 | -10.4 | -7 |
| % Growth | 23.6% | 17.8% | -48.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$1 | -$0 |